听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览MELANOMA RESEARCH期刊下所有文献
  • A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.

    abstract::Conjunctival melanoma is a rare disease, and little is known about its molecular background. Here, we present the case of a 48-year-old patient with conjunctival melanoma and metachronic lymph node and skin metastasis with KRAS p.K117Y mutation in exon 4 in all the lesions. The cancer genome interpreter predicted this...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0000000000000423

    authors: Del Carpio Huerta LP,Mas Castells M,Anguera Palacios G,Sullivan I,Gonzalez Vidal A,Majem Tarruella M

    更新日期:2018-04-01 00:00:00

  • PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.

    abstract::Regional lymph nodes are affected frequently by melanoma metastasis. Its microenvironment may be associated with tumor progression. We investigated sentinel nodes with and without tumor and negative nodes surrounding positive nodes, looking for patterns related to tumor immune interaction and lymphovascular progressio...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000396

    authors: Alessi C,Scapulatempo Neto C,Viana CR,Vazquez VL

    更新日期:2017-12-01 00:00:00

  • Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.

    abstract::Cutaneous melanoma is one of the most lethal cancers because of its increased rate of metastasis and resistance to available therapeutic options. Early studies indicate that metformin has beneficial effects on some types of cancer, including melanoma. To clarify knowledge of the mechanism of action of metformin on thi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000391

    authors: de Souza Neto FP,Bernardes SS,Marinello PC,Melo GP,Luiz RC,Cecchini R,Cecchini AL

    更新日期:2017-12-01 00:00:00

  • Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

    abstract::BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutati...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CMR.0000000000000398

    authors: Hallmeyer S,Gonzalez R,Lawson DH,Cranmer LD,Linette GP,Puzanov I,Taback B,Cowey CL,Ribas A,Daniels GA,Moore T,Gibney GT,Tawbi H,Whitman E,Lee G,Mun Y,Liu S,Hamid O

    更新日期:2017-12-01 00:00:00

  • Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.

    abstract::Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations - BRAF A598_T599insV and V60...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000376

    authors: Rogiers A,Vander Borght S,Tuand K,Wolter P,Stas M,Boecxstaens V,Garmyn M,van den Oord JJ,Vandenberghe P,Bechter O

    更新日期:2017-10-01 00:00:00

  • Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.

    abstract::The universal second messenger cAMP regulates numerous cellular processes. Although the cAMP-signaling pathway leads to induction of gene transcription, it remains unknown whether this pathway contributes toward suppression of transcription. Here, we show that blockade of cAMP signaling using MDL12330A led to an incre...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000363

    authors: Lakhter AJ,Naidu SR

    更新日期:2017-10-01 00:00:00

  • Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.

    abstract::The CXCR4 chemokine receptor plays an essential role in the homing of cells to organs expressing its ligand, CXCL12. CXCR4 expressed on tumor cells might regulate their traffic during metastasis. Here, we investigated whether the activation of CXCR4 on B16 murine melanoma cells regulates biological functions associate...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000346

    authors: Mendt M,Cardier JE

    更新日期:2017-08-01 00:00:00

  • Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.

    abstract::In this study, we aimed to evaluate the feasibility and efficacy of peptide-pulsed dendritic cell (DC) vaccine in combination with carboplatin and paclitaxel chemotherapy (DCCP) for patients with stage IV melanoma previously treated with dacarbazine-containing regimen. Six HLA-A24 and 3 HLA-A02 patients were treated w...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000342

    authors: Fukuda K,Funakoshi T,Sakurai T,Nakamura Y,Mori M,Tanese K,Tanikawa A,Taguchi J,Fujita T,Okamoto M,Amagai M,Kawakami Y

    更新日期:2017-08-01 00:00:00

  • The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?

    abstract::CD8 T-cell infiltration of metastatic melanoma may be a useful biomarker for prediction of prognosis and response to therapy. The heterogeneous distribution of CD8 T cells within a single tumor, and across different tumors within a single patient, may complicate quantification of infiltration. However, the impact of h...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000330

    authors: Obeid JM,Hu Y,Erdag G,Leick KM,Slingluff CL Jr

    更新日期:2017-06-01 00:00:00

  • Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.

    abstract::Radiotherapy after lymph node dissection is recommended in high-risk melanoma cases. The aim of this study is to assess whether intensity-modulated radiotherapy (IMRT) offers advantages over three-dimensional conformal radiotherapy (3DCRT) in the groin nodal basin. Fifteen consecutively treated patients (5 3DCRT and 1...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000304

    authors: Adams G,Foote M,Brown S,Burmeister B

    更新日期:2017-02-01 00:00:00

  • The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.

    abstract::Recently, TROG 02.01 results showed that in stage III melanoma patients with nodal metastasis, adjuvant radiation to lymph node basin after nodal dissection improves lymph node field relapse without an overall survival (OS) benefit. However, this trial was neither designed nor powered to detect an OS difference. In th...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000292

    authors: Danish HH,Patel KR,Switchenko JM,Gillespie TW,Jhaveri J,Chowdhary M,Abugideiri M,Delman KA,Lawson DH,Khan MK

    更新日期:2016-12-01 00:00:00

  • Primary malignant melanoma of the urinary bladder: clinical, morphological, and molecular analysis of five cases.

    abstract::The aim of our study was to evaluate the clinical and morphological features of primary malignant melanomas of the urinary bladder. We obtained information on five such cases from three different institutions. These were three men and two women between 52 and 76 years of age. Three tumors presented with hematuria, one...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000300

    authors: Karabulut YY,Erdogan S,Sayar H,Ergen A,Ertoy Baydar D

    更新日期:2016-12-01 00:00:00

  • Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.

    abstract::Galectin-9, a β-galactoside-binding protein, is defined as a negative regulator of T helper 1 (Th1) immune responses, favoring Th2 bias. Systemic immunity in patients with metastatic melanoma is predominantly Th2 biased. We hypothesized that galectin-9 can modulate systemic immunity toward Th2 polarization in patients...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000281

    authors: Enninga EA,Nevala WK,Holtan SG,Leontovich AA,Markovic SN

    更新日期:2016-10-01 00:00:00

  • Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.

    abstract:BACKGROUND:Melanoma is the leading cause of death from skin cancers and its etiology is complex. Recent discoveries related to genetic risk factors are helping us to understand melanoma pathogenesis better. Nuclear factor-κB (NF-κB) has a critical role in immunity, inflammation, and tumor growth. The 94ins/del ATTG (rs...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000267

    authors: Escobar GF,Arraes JA,Bakos L,Ashton-Prolla P,Giugliani R,Callegari-Jacques SM,Santos S,Bakos RM

    更新日期:2016-08-01 00:00:00

  • A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma.

    abstract::A 58-year-old man with indolent metastatic BRAF mutant melanoma presented with several days' history of progressive ataxia and dysdiadochokinesia. His PET/computed tomography restaging scan indicated two new fluorine-18-fluorodeoxyglucose-avid mesenteric lymph nodes. Meanwhile, his MRI brain and whole spine were withi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000264

    authors: Lee SF,Atkinson V

    更新日期:2016-08-01 00:00:00

  • Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database.

    abstract::Superficial spreading melanoma (SSM) is the most common type of melanoma. Large, population-based studies analyzing the incidence and survival of SSM are limited. This retrospective study was designed to evaluate demographic factors influencing the incidence and survival of SSM using a national population-based databa...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000245

    authors: Singh P,Kim HJ,Schwartz RA

    更新日期:2016-08-01 00:00:00

  • Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma.

    abstract::Accumulating evidence has suggested that the XRCC1 Arg399Gln and Arg194Trp polymorphisms might be related to cutaneous melanoma susceptibility. However, epidemiologic findings have been inconsistent. We have assessed reported studies by meta-analysis to perform a more precise estimation of the association between the ...

    journal_title:Melanoma research

    pub_type: 杂志文章,meta分析

    doi:10.1097/CMR.0000000000000246

    authors: Jiang H,Xu W,Zhang F,Wei L,Wang Y,Wang Y,Liu C

    更新日期:2016-06-01 00:00:00

  • Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies.

    abstract::An increased risk of melanoma has been variously reported in patients with chronic lymphocytic leukaemia (CLL), analogous with other immunosuppressed populations. To fully assess this association, we performed a systematic review and meta-analysis of available evidence from observational cohort studies. All such longi...

    journal_title:Melanoma research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/CMR.0000000000000219

    authors: Olsen CM,Lane SW,Green AC

    更新日期:2016-04-01 00:00:00

  • BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

    abstract::Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000214

    authors: Sloot S,Zager JS,Kudchadkar RR,Messina JL,Benedict JJ,Gonzalez RJ,DeConti R,Turner LM,McCardle T,Smalley KS,Weber JS,Sondak VK,Gibney GT

    更新日期:2016-02-01 00:00:00

  • Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma.

    abstract::To investigate the diagnostic value of ultrasound-guided core needle biopsy (US-CNB) in suspected cases of lymph node metastasis from cutaneous melanoma. All patients with cutaneous melanoma followed in Saint-Louis Hospital between 2006 and 2010 who underwent US-CNB for suspicion of melanoma lymph node metastasis were...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000161

    authors: Bohelay G,Battistella M,Pagès C,de Margerie-Mellon C,Basset-Seguin N,Viguier M,Kerob D,Madjlessi N,Baccard M,Archimbaud A,Comte C,Mourah S,Porcher R,Bagot M,Janin A,De Kerviler E,Lebbé C

    更新日期:2015-12-01 00:00:00

  • Replacing surrogate measures by direct quantification of ultraviolet radiation exposure in registry-based analyses of seasonality of melanoma diagnoses.

    abstract::Seasonal variation in melanoma diagnoses has been observed in numerous studies that used calendar time indicators. Depending on the latitude (and altitude) of the study region, the magnitude of seasonal and year-to-year variation of ultraviolet radiation (UVR) is neglected in these studies. An alternative approach com...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000205

    authors: Keller AK,Uter W,Pfahlberg AB,Radespiel-Tröger M,Mayer I,Gefeller O

    更新日期:2015-12-01 00:00:00

  • Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.

    abstract::Microphthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. We previously reported that Mitf expression, as detected by immunohistochemical analysis, is an independent prognostic marker in patients with intermediate-thickness melanoma. However, the clinical significance of Mit...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000195

    authors: Naffouje S,Naffouje R,Bhagwandin S,Salti GI

    更新日期:2015-12-01 00:00:00

  • A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes.

    abstract::The aim of this study was to determine the apoptotic effects, toxicity, and radiosensitization of total low dose irradiation delivered at a high dose rate in vitro to melanoma cells, normal human epidermal melanocytes (HEM), or normal human dermal fibroblasts (HDF) and to study the effect of mitochondrial inhibition i...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000174

    authors: Sarojini S,Pecora A,Milinovikj N,Barbiere J,Gupta S,Hussain ZM,Tuna M,Jiang J,Adrianzen L,Jun J,Catello L,Sanchez D,Agarwal N,Jeong S,Jin Y,Remache Y,Goy A,Ndlovu A,Ingenito A,Suh KS

    更新日期:2015-10-01 00:00:00

  • Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

    abstract::Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patient data using a pre...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000185

    authors: Ahmad SS,Qian W,Ellis S,Mason E,Khattak MA,Gupta A,Shaw H,Quinton A,Kovarikova J,Thillai K,Rao A,Board R,Nobes J,Dalgleish A,Grumett S,Maraveyas A,Danson S,Talbot T,Harries M,Marples M,Plummer R,Kumar S,Nathan

    更新日期:2015-10-01 00:00:00

  • Surgical management of metastatic melanoma in the era of targeted systemic therapies.

    abstract::Treatment strategies for metastatic melanoma have changed markedly in recent times due to the advent of targeted systemic therapies. In addition to these developments, surgery remains a useful adjunct that can confer survival benefits in selected patients. In this review, we examine the current literature to highlight...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/CMR.0000000000000128

    authors: O'Leary DP,Byrnes KG,Power DG,Redmond HP

    更新日期:2015-02-01 00:00:00

  • Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

    abstract::Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of ipilimumab administ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000108

    authors: Berrocal A,Arance A,Lopez Martin JA,Soriano V,Muñoz E,Alonso L,Espinosa E,Lopez Criado P,Valdivia J,Martin Algarra S,Spanish Melanoma Group.

    更新日期:2014-12-01 00:00:00

  • Blood DNA methylation, nevi number, and the risk of melanoma.

    abstract::Germline mutations determining increased cutaneous malignant melanoma (CMM) risk have been identified in familial and sporadic CMM cases, but they account only for a small proportion of CMM cases. Recent evidence suggests that germline epimutations (e.g. DNA methylation alterations), which can be inherited similarly t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000112

    authors: Pergoli L,Favero C,Pfeiffer RM,Tarantini L,Calista D,Cavalleri T,Angelici L,Consonni D,Bertazzi PA,Pesatori AC,Landi MT,Bollati V

    更新日期:2014-10-01 00:00:00

  • Comparing characteristics of melanoma cases arising in health maintenance organizations with state and national registries.

    abstract::Datasets from large health maintenance organizations (HMOs), particularly those with established cancer registries that report to the Surveillance, Epidemiology, and End Results program, are potentially excellent resources for studying melanoma epidemiology and outcomes. However, generalizability of the findings beyon...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000087

    authors: Asgari MM,Eide MJ,Warton M,Fletcher SW

    更新日期:2014-08-01 00:00:00

  • Accuracy of sentinel lymph node dissection for melanoma staging in the presence of a collision tumour with a lymphoproliferative disease.

    abstract::Sentinel lymph node dissection (SLND) identifies melanoma patients with metastatic disease who would benefit from radical lymph node dissection (RLND). Rarely, patients with melanoma have an underlying lymphoproliferative disease, and melanoma metastases might develop as collision tumours in the sentinel lymph node (S...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000098

    authors: Gero D,Queiros da Mota V,Boubaker A,Berthod G,de Leval L,Demartines N,Matter M

    更新日期:2014-08-01 00:00:00

  • The transcription factor CUTL1 is associated with proliferation and prognosis in malignant melanoma.

    abstract::The transcription factor CUTL1 (CCAAT displacement protein 1) has been reported to participate in the proliferation of diverse types of cancer. In the present study, we investigated the potential involvement of CUTL1 in the proliferation of malignant melanoma. We found that CUTL1 expression was upregulated in malignan...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000064

    authors: Fan X,Wang H,Zhou J,Wang S,Zhang X,Li T,Nie Y,Liu B

    更新日期:2014-06-01 00:00:00

  • MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.

    abstract::The p53 pathway regulates stress response, and variations in p53, MDM2, and MDM4 may predispose an individual to tumor development. The aim of this study was to study the impact of genetic variation on sporadic and hereditary melanoma. We have analyzed a combination of three functionally relevant variants of the p53 p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000063

    authors: Thunell LK,Bivik C,Wäster P,Fredrikson M,Stjernström A,Synnerstad I,Rosdahl I,Enerbäck C

    更新日期:2014-06-01 00:00:00

  • Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.

    abstract::In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melano...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/CMR.0000000000000056

    authors: Bedikian AY,Garbe C,Conry R,Lebbe C,Grob JJ,Genasense Melanoma Study Group.

    更新日期:2014-06-01 00:00:00

  • A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

    abstract::We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion i...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000036

    authors: Lau DK,Andrews MC,Turner N,Azad AA,Davis ID,Cebon JS

    更新日期:2014-04-01 00:00:00

  • The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival.

    abstract::The management of melanoma brain metastases (MBM) includes different therapeutic modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of treatments, survival remains poor, exceeding 1 year only in patients with solitary metastases and absence of extracranial disease. A total of 115 consecutiv...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000029

    authors: Vecchio S,Spagnolo F,Merlo DF,Signori A,Acquati M,Pronzato P,Queirolo P

    更新日期:2014-02-01 00:00:00

  • Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.

    abstract::Interleukin-24 (IL-24)/melanoma differentiation-associated gene-7 (mda-7) is a unique cytokine-tumor suppressor that displays ubiquitous antitumor properties and tumor-specific killing activity. Oncostatin M (OSM) is the most active IL-6-type cytokine and inhibits the proliferation of various solid tumor cell lines. M...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000038

    authors: Xu Y,Zhang F,Qin L,Miao J,Sheng W,Xie Y,Xu X,Yang J,Qian H

    更新日期:2014-02-01 00:00:00

  • Interleukin-6-induced Twist and N-cadherin enhance melanoma cell metastasis.

    abstract::Melanoma patients frequently have elevated serum levels of interleukin-6 (IL-6), which is correlated with a poor prognosis. IL-6 activates STAT3 phosphorylation, inducing the transcription of genes that regulate tumor cell proliferation and antiapoptosis. In addition, recent evidence suggests that IL-6 induces the epi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000021

    authors: Na YR,Lee JS,Lee SJ,Seok SH

    更新日期:2013-12-01 00:00:00

  • Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.

    abstract::Dermatologic toxicity is a known reaction of ipilimumab and vemurafenib. Because of the lack of effective treatments and aggressive nature of melanoma, treatments are often discontinued and new treatments are initiated in rapid succession. We report what we believe to be the first case of cumulative dermatologic toxic...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000018

    authors: Ludlow SP,Pasikhova Y

    更新日期:2013-12-01 00:00:00

  • Clinical significance of serum M30 and M65 levels in melanoma.

    abstract::M30 and M65 are relatively new assays that detect different circulating forms of the epithelial cell structural protein cytokeratin 18. This study was carried out to investigate the serum levels of M30 and M65 in patients with melanoma and the relationship with tumor progression and known prognostic parameters. Fifty-...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328363e4ab

    authors: Tas F,Karabulut S,Serilmez M,Yildiz I,Sen F,Ciftci R,Duranyildiz D

    更新日期:2013-10-01 00:00:00

  • Compliance with guidelines in the surgical management of cutaneous melanoma across the USA.

    abstract::The National Comprehensive Cancer Network has formulated guidelines for the management of cutaneous malignant melanoma with regard to resection margins (RMs) and regional staging. The aim of this study was to assess compliance with these recommendations in the general population of the USA. The Surveillance, Epidemiol...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32836254bd

    authors: Wasif N,Gray RJ,Bagaria SP,Pockaj BA

    更新日期:2013-08-01 00:00:00

  • Ipilimumab-induced acute severe colitis treated by infliximab.

    abstract::Ipilimumab (anti-CTLA-4 antibody) is a new tool for the treatment of metastatic melanoma patients that has led to an improvement in survival rates worldwide. New types of toxicities have been described with ipilimumab called 'immune-related adverse events' or irAEs. Here, we report an acute and steroid resistant case ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32835fb524

    authors: Pagès C,Gornet JM,Monsel G,Allez M,Bertheau P,Bagot M,Lebbé C,Viguier M

    更新日期:2013-06-01 00:00:00

230 条记录 2/6 页 « 123456 »